Coeliac disease

EQS-News: Immunic to Host Virtual Celiac Disease R&D Day to Highlight Current Pathways for Drug Development and Unmet Medical Need

Retrieved on: 
Monday, February 13, 2023
ET, Hepatology, Conference call, Conference, Internal medicine, DRS, Coeliac disease, Degenerative disease, Therapy, Mayo Clinic, Patient, Clinical trial, Disease, Division, Part, Research, Management, Dentistry, Pharmaceutical industry, Rheumatology, Webcast, Short course immune induction therapy, Gastroenterology

“We look forward to hosting this deep-dive discussion, focused on the current challenges of treating celiac disease with two, such renowned thought leaders as Drs.

Key Points: 
  • “We look forward to hosting this deep-dive discussion, focused on the current challenges of treating celiac disease with two, such renowned thought leaders as Drs.
  • Murray and Schumann,” stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic.
  • Registrants will receive a confirmation email containing a link for online participation or a telephone number for dial in access.
  • An archived replay of the webcast will be available approximately one hour after completion on Immunic’s website at: ir.imux.com/events-and-presentations .

New Down Syndrome Resource Available in Spanish and Japanese

Retrieved on: 
Thursday, December 29, 2022
Dementia, Centro, Degenerative disease, American Medical Association, Diabetes, CUSD, Journal, Sleep apnea, Research, Registry, Osteoporosis, COVID-19, Down syndrome, Ministry of Health (Saudi Arabia), Axis (anatomy), Leukemia, Guideline, Cardiovascular disease, Thyroid disease, Universidad, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Coeliac disease, Obesity, Congress, NIH, Down, El Centro, California, Dietary supplement, Medical device, Pharmaceutical industry, Tourism, Health, Behavior

GLOBAL is working to expand the topics to include sleep apnea, solid tumors, leukemia, vision/eye care, and physical therapy and fitness.

Key Points: 
  • GLOBAL is working to expand the topics to include sleep apnea, solid tumors, leukemia, vision/eye care, and physical therapy and fitness.
  • “GLOBAL is pleased to be able to reach Spanish and Japanese speakers who have Down syndrome and their families in the U.S. in collaboration from the National Institutes of Health/DS-Connect®,” says Michelle Sie Whitten, President & CEO of the Global Down Syndrome Foundation.
  • “It is so important for me and other people with Down syndrome to have this in Spanish,” says Yadiro Carrillo, a 32-year-old self-advocate and entrepreneur who happens to have Down syndrome.
  • To learn more about the GLOBAL Adult Guideline and download your copy today, visit www.globaldownsyndrome.org/medical-care-guidelines-for-adults/
    To learn more about Global Down Syndrome Foundation, visit www.globaldownsyndrome.org

New Valerie Fund Center at Stony Brook Children’s Hospital

Retrieved on: 
Wednesday, December 7, 2022
Oncology, Health, Consumer, Hospitals, Parenting, Children, General Health, Travel, Hematology, HIV, MD, Partnership, Patient, Cancer, Friends, Infant, Division, VF, Bed, Valerie, Pediatric Hematology and Oncology, Growth, Coeliac disease, Hospital, Degenerative disease, Community Hospitals and Wellness Centers, Medicine

The Valerie Fund is excited to announce its newest Valerie Fund Center at Stony Brook Childrens Hospital in Stony Brook, New York.

Key Points: 
  • The Valerie Fund is excited to announce its newest Valerie Fund Center at Stony Brook Childrens Hospital in Stony Brook, New York.
  • Stony Brook Childrens Hospital is delighted about our new relationship with The Valerie Fund, says Carolyn Milana, MD, Physician-in-Chief at Stony Brook Childrens Hospital.
  • We are thrilled to welcome Stony Brook Childrens Hospital as our newest Valerie Fund Center, says Neil Yaris, The Valerie Fund Board Chair.
  • About Stony Brook Childrens Hospital:
    With 104 beds, Stony Brook Childrens Hospital is Suffolk Countys only childrens hospital.

The Worldwide Lactose-Free Dairy Industry is Projected to Reach $24.36 Billion by 2031 - ResearchAndMarkets.com

Retrieved on: 
Monday, December 5, 2022
Food, Beverage, Retail, Benchmarking, Dairy, Stomach, Bloating, Degenerative disease, Lactose intolerance, Ultrafiltration, Lactase, Cancer, Hunger, Coeliac disease, Ice cream, Cardiovascular disease, Aspergillus niger, Lactose, Form, Obesity, Yeast, Allergy, Abdominal pain, QSR International, Porter's five forces analysis, Distribution, Aspergillus oryzae, Milk, Dairy product

The global lactose-free dairy market was valued at $11.45 billion in 2021, and is projected to reach $24.36 billion by 2031, growing at a CAGR of 8% from 2022 to 2031.

Key Points: 
  • The global lactose-free dairy market was valued at $11.45 billion in 2021, and is projected to reach $24.36 billion by 2031, growing at a CAGR of 8% from 2022 to 2031.
  • Lactose-free dairy products are created by adding lactase to ordinary cow milk.
  • Lactose-free dairy products have a similar flavor, texture, and nutritional profile to conventional milk and milk products that are available in the market.
  • The report includes the analysis of the regional as well as global lactose-free dairy market trends, key players, market segments, application areas, and market growth strategies.

Nemysis Ltd and Faran S.A. Sign a Strategic Agreement to Cooperate for the Development of Endopeptidase E40 for Celiac Disease

Retrieved on: 
Friday, December 2, 2022
Coeliac disease, Gynaecology, Safety, Epitope, LTD, Autumn, Pathology, Gluten-sensitive enteropathy–associated conditions, Anemia, Patient, Nutrient deficiency, Strategic Cooperation Agreement, Trypsin, Pharmaceutical industry, Dietary supplement, Orthopedic surgery, Nephrology, Endocrinology, Cardiology, Gastroenterology, Rheumatology, Dermatology, E40, Hematology

"Faran has a longstanding tradition in bringing to the Greek market innovative products and providing innovative solutions to tackle highly prevalent unmet medical conditions.

Key Points: 
  • "Faran has a longstanding tradition in bringing to the Greek market innovative products and providing innovative solutions to tackle highly prevalent unmet medical conditions.
  • The company has established over the years several strategic partnerships with established pharma companies from all over the world," said Danilo Casadei Massari, Nemysis's Chairman, and CEO.
  • "We are pleased to cooperate in the late-stage development of E40, a novel enzymatic therapy for gluten degradation which will bring relief to the many patients suffering from symptoms of Celiac Disease.
  • E40 will perfectly fit in our portfolio and complement our presence in the specific field."

Everly Health Unveils Spotwell™ Technology in New Mobile App

Retrieved on: 
Tuesday, November 15, 2022
Apps, Applications, Technology, Medical Devices, Other Technology, Health Technology, Software, Health, General Health, Data Management, Coeliac disease, Food allergy, IPhone, App store optimization, Collection, App store, Health, IOS, Medical device, Natalism, Vitamin

The app features Spotwell, Everly Healths proprietary machine vision technology that uses an iPhone camera to validate blood sample sufficiency in real-time.

Key Points: 
  • The app features Spotwell, Everly Healths proprietary machine vision technology that uses an iPhone camera to validate blood sample sufficiency in real-time.
  • Spotwell is another innovation milestone from Everly Health, transforming diagnostics for millions of people.
  • The Spotwell technology is built to engage our test-takers and innovate by creating increased efficiency in the blood collection method, said Nick Parker, Chief Technology Officer at Everly Health.
  • Headquartered in Austin, Texas, Everly Health is the parent company to Everlywell, Everly Health Solutions, Natalist, and Everly Diagnostics.

Gluten Free Food Global Market Report 2022: Increasing Prevalence of IBS and Celiac Disease Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, November 14, 2022
Retail, Fitness & Nutrition, Health, Food, Beverage, NCBI, Flour, Lunch, Absorption, Inulin, United Nations Foundation, Food, Irritable bowel syndrome, Degenerative disease, Chicory, IBS, Food industry, National Center for Appropriate Technology, Coeliac disease, National Center for Biotechnology Information, Condiment, Dry, Bread, Growth, Fructose, Nutrient, Water, Breakfast, Incidence

The "Gluten Free Food Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Gluten Free Food Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • The regions covered in the gluten free food market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • Increasing incidence of irritable bowel syndrome (IBS) and celiac diseases is expected to contribute to higher demand for gluten free food products.
  • Therefore, the rising incidence of IBS and celiac diseases is projected to boost the demand for gluten free food over the coming years.

The American Society for Clinical Pathology Expands List of Commonly Used Tests Physicians and Patients Should Question in Collaboration with ASCLS and ASM

Retrieved on: 
Tuesday, November 8, 2022
Plasma, Viral hepatitis, Human, Physician, Publication, Industry, Immunoglobulin G, Society, Patient, CMA Code of Ethics and Professionalism, Consumer, Professional, DLM, Decision-making, ASCP, Glycated hemoglobin, ENA, Certification, Disease, Connective tissue disease, EBV, Marie Cassidy, Neutropenia, Autoimmune hepatitis, INR, Student, Policy, Education, Urine, Partnership, Chlamydia trachomatis, American Society for Clinical Laboratory Science, ANA, Pathology, Neisseria gonorrhoeae, Medicine, DOAC, Choosing Wisely, ASM, Coeliac disease, Knowledge, MPH, AIH, Pharmaceutical industry, Medical imaging, Vaccine, Ethics, MD, Chlamydia

The lists of targeted, evidence-based recommendations are designed to support conversations between patients and physicians about what care is really necessary.

Key Points: 
  • The lists of targeted, evidence-based recommendations are designed to support conversations between patients and physicians about what care is really necessary.
  • The new Choosing Wisely recommendations, developed by ASCP in collaboration with ASCLS, include:
    1.Don't repeat HbA1c testing within 3 months of a previous result.
  • 2.Don't perform an extensive work-up in otherwise healthy neutropenic patients of African or Middle Eastern ancestry prior to Duffy-null phenotype testing.
  • The American Society for Microbiology (ASM) is the largest single life science society, composed of 30,000 scientists and health professionals.

Global Celiac Disease Market Research Report 2022: Players Include Abbott Laboratories, AbbVie, Bayer and Calypso Biotech - ResearchAndMarkets.com

Retrieved on: 
Monday, November 7, 2022
Research, Other Health, General Health, Pharmaceutical, Consumer, Technology, Fitness & Nutrition, Science, Other Consumer, Biotechnology, Health, Food Tech, Other Science, People, News, Bayer, Down syndrome, Restaurant, Abbott Laboratories, Growth, Association, Patient, Adoption, Nutrient, CAGR, Government, Coeliac disease, Degenerative disease, Iron, Disease, School, Rheumatoid arthritis, Bone density, COVID-19, Novartis, Siemens, Johnson & Johnson, Hospital, Amgen, Addison's disease, Calcium, Eli Lilly and Company, Infertility, Risk, Awareness, Cancer, BioLineRx, Lipid, Dietary supplement, Pharmaceutical industry, Marketing

The "Global Celiac Disease Market Research and Forecast 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Celiac Disease Market Research and Forecast 2022-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global celiac disease market is anticipated to grow significantly at a CAGR of 8.5% during the forecast period.
  • The organization of various awareness programs and initiatives taken by the government in various nations for the treatment of celiac disease is a major factor that is driving the growth of the global celiac disease market.
  • The key players of the global celiac disease market include Abbott Laboratories, Eli Lilly & Co, Novartis AG, Johnson & Johnson, BioLineRx Ltd., Amgen Inc., Siemens AG, and Bayer AG among others.

Equillium Announces Initiation of Phase 1 study of EQ102, A First-in-Class Multi-Cytokine Inhibitor of IL-15 and IL-21 Targeting Celiac Disease

Retrieved on: 
Wednesday, November 2, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, MAD, Risk, Adult, T, Inflammation, Peptide, MCP, CED, Degenerative disease, SEC, Department of Medicine – University of Pamplona, Research, HLA, Nasdaq, Disease, Alopecia areata, Feedback, Trial of the century, Department, EDGAR, Safety, Incidence, University, Private Securities Litigation Reform Act, Medicine, Cytokine, Patient, Itolizumab, Coeliac disease, Therapy, De novo, Forward-looking statement, JAK, Gene, Autoimmunity, Intestinal villus, Pharmaceutical industry, Medical imaging

Following the SAD/MAD portion of this study Equillium plans to evaluate the biological activity of EQ102 in subjects with celiac disease.

Key Points: 
  • Following the SAD/MAD portion of this study Equillium plans to evaluate the biological activity of EQ102 in subjects with celiac disease.
  • We believe this may be an optimal approach to treating patients with celiac disease, and we look forward to reporting initial clinical data from this study next year.
  • Following the MAD portion of this study, Part C of the study will evaluate the biological activity of EQ102 in subjects with celiac disease.
  • Equillium is currently enrolling patients in a Phase 1 study of EQ102, including healthy volunteers and celiac disease patients.